Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
|
|
ROCKWELL MEDICAL, INC. (RMTI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Investor presentation, Quarterly results |
| 05/15/2023 |
8-K
| Investor presentation, Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 03/12/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 10/24/2019 |
8-K
| Quarterly results|
Docs:
|
"Rockwell Medical, Inc. Provides Business Update - Encouraging progress for Triferic® portfolio - - Conference call at 8:30 am ET on Friday, October 25, 2019 - WIXOM, Mich., October 24, 2019 — Rockwell Medical, Inc. , a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease , today provided a business update and information related to the launch of Dialysate Triferic® , and reported preliminary third quarter 2019 financial results. The Company will host a conference call on Friday, October 25, 2019 at 8:30 am ET to review these updates. “Our mission is to transform anemia management in a wide variety of disease states across the globe while improving patients' lives. We believe Triferic is one of the most innovati..." |
|
| 08/08/2019 |
8-K
| Quarterly results |
| 05/09/2019 |
8-K
| Quarterly results |
| 03/14/2019 |
8-K
| Quarterly results |
| 11/13/2018 |
8-K
| Quarterly results |
| 08/14/2018 |
8-K
| Quarterly results |
| 05/10/2018 |
8-K
| Quarterly results|
Docs:
|
"Rockwell Medical Reports First Quarter 2018 Results Conference call at 4:30 p.m. EDT today, May 10 WIXOM, Mich., May 10, 2018 -- Rockwell Medical, Inc. , a fully-integrated specialty pharmaceutical company targeting end-stage renal disease and chronic kidney disease with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the first quarter ended March 31, 2018. Q1 2018 Financial Highlights Sales were $14.9 million, an increase of 2.4% over the first quarter of 2017. Gross profit in the first quarter of 2018 was $29,507, compared with $2.4 million in the first quarter of 2017; gross profit from our concentrate business was offset by expenses related to our drug business. Net Loss for the first quarter o..." |
|
| 03/15/2018 |
8-K
| Quarterly results |
| 11/08/2017 |
8-K
| Quarterly results|
Docs:
|
"Rockwell Medical Reports Third Quarter Results Conference Call and Webcast Today at 4:30 p.m. EST. WIXOM, Mich., Nov. 08, 2017 -- Rockwell Medical, Inc. , reported results for the three and nine months ended Sept. 30, 2017. Q3 2017 Financial Highlights Sales were $14.6 million, an increase of 14.1% or $1.8 million over third quarter of 2016. Gross profit was $1.1 million, compared to $1.6 million in Q3 2016. SG&A expense was $4.8 million, compared $5.1 million in Q3 2016. R&D expense was $1.3 million, same as Q3 2016. Net loss was $5.1 million or per share compared to a $4.6 million loss or per share in Q3 2016. Cash and investments were $38.9 million as of September 30, 2017. Net working capital was $53.6 million as of September 30, 2017 compared to $56.1 million at June 30, 2017. Q3 YTD ..." |
|
| 08/09/2017 |
8-K
| Quarterly results |
| 05/10/2017 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 03/15/2017 |
8-K
| Form 8-K - Current report |
| 08/08/2016 |
8-K
| Quarterly results |
| 05/13/2016 |
8-K
| Quarterly results|
Docs:
|
"Rockwell Medical Reports First Quarter Results WIXOM, Mich., May 10, 2016 -- Rockwell Medical, Inc. , a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the first quarter of 2016. Q1 2016 Financial Highlights SG&A expense was $5.0 million compared $5.3 million in Q1 2015. R&D expense was $1.3 million compared to $0.8 million in Q1 2015. Income tax expense was $0.4 million, related to the $4 million Wanbang license payment. Net loss was million or per share compared to million or per share in Q1 2015. Cash and investments were $69.4 million as of March 31, 2016.",
"Transcript of May 10, 2016 earnings call" |
|
| 02/29/2016 |
8-K
| Quarterly results|
Docs:
|
"Rockwell Medical Reports Fourth Quarter and Fiscal 2015 Results WIXOM, Mich., Feb. 29, 2016 -- Rockwell Medical, Inc. , a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the fourth quarter of 2015 and total 2015 year results. Q4 2015 Financial Highlights Sales were $14.1 million, compared to $14.4 million in Q4 2014. Gross profit was $2.1 million, 3.3 % less than Q4 2014. Gross profit margins were 14.5%, compared to 17.8% in Q4 2014. SG&A expense was $6.1 million, compared $5.9 million in Q4 2014. R&D expense was $2.0 million compared to $1.7 million in Q4 2014. Net loss was million or per s..." |
|
| 11/09/2015 |
8-K
| Quarterly results |
| 08/04/2015 |
8-K
| Quarterly results |
| 05/07/2015 |
8-K
| Quarterly results |
| 11/10/2014 |
8-K
| Quarterly results |
| 07/31/2014 |
8-K
| Quarterly results |
| 05/12/2014 |
8-K
| Quarterly results |
| 02/26/2014 |
8-K
| Quarterly results |
| 11/05/2013 |
8-K
| Form 8-K - Current report |
| 08/01/2013 |
8-K
| Form 8-K - Current report |
| 05/08/2013 |
8-K
| Form 8-K - Current report |
| 11/08/2012 |
8-K
| Form 8-K - Current report |
| 08/07/2012 |
8-K
| Form 8-K - Current report |
|
|
|